心血管康复医学杂志
心血管康複醫學雜誌
심혈관강복의학잡지
JOURNAL OF CARDIOVASCULAR REHABILITATION MEDICINE
2015年
2期
185-188
,共4页
心肌梗死%血管成形术,气囊,冠状动脉%氯吡格雷
心肌梗死%血管成形術,氣囊,冠狀動脈%氯吡格雷
심기경사%혈관성형술,기낭,관상동맥%록필격뢰
Myocardial infarction%Angioplasty,balloon,coronary%Clopidogrel
目的:探讨氯吡格雷在非ST 段抬高心肌梗死(NSTEMI)患者急诊介入治疗时的应用价值。方法:选择2012年1月~2013年2月于本院治疗的168例NSTEMI患者,随机分为氯吡格雷组(84例)与噻氯匹啶组(84例),均急诊行冠脉介入治疗。观察两组患者的临床疗效并进行对比。结果:术后28d ,与噻氯匹定组比较,氯吡格雷组TIMI 3级血流比例(88.1%比91.7%)、白细胞计数[(4.0±2.9)×109/L比(7.2±2.3)×109/L]、血小板计数[(101±35)×109/L比(141±39 )×109/L ]明显增多,轻度出血比例(40.5%比19.0%) 显著减少( P<0.05或 P<0.01);经6个月随访,与噻氯吡啶组比较,氯吡格雷组心血管事件(60.7%比27.4%)、不良反应发生率(14.3%比10.8%) 均明显降低( P均<0.05)。结论:氯吡格雷用于非S T 段抬高心肌梗死患者急诊冠脉介入治疗疗效满意,安全性高,值得推广。
目的:探討氯吡格雷在非ST 段抬高心肌梗死(NSTEMI)患者急診介入治療時的應用價值。方法:選擇2012年1月~2013年2月于本院治療的168例NSTEMI患者,隨機分為氯吡格雷組(84例)與噻氯匹啶組(84例),均急診行冠脈介入治療。觀察兩組患者的臨床療效併進行對比。結果:術後28d ,與噻氯匹定組比較,氯吡格雷組TIMI 3級血流比例(88.1%比91.7%)、白細胞計數[(4.0±2.9)×109/L比(7.2±2.3)×109/L]、血小闆計數[(101±35)×109/L比(141±39 )×109/L ]明顯增多,輕度齣血比例(40.5%比19.0%) 顯著減少( P<0.05或 P<0.01);經6箇月隨訪,與噻氯吡啶組比較,氯吡格雷組心血管事件(60.7%比27.4%)、不良反應髮生率(14.3%比10.8%) 均明顯降低( P均<0.05)。結論:氯吡格雷用于非S T 段抬高心肌梗死患者急診冠脈介入治療療效滿意,安全性高,值得推廣。
목적:탐토록필격뢰재비ST 단태고심기경사(NSTEMI)환자급진개입치료시적응용개치。방법:선택2012년1월~2013년2월우본원치료적168례NSTEMI환자,수궤분위록필격뢰조(84례)여새록필정조(84례),균급진행관맥개입치료。관찰량조환자적림상료효병진행대비。결과:술후28d ,여새록필정조비교,록필격뢰조TIMI 3급혈류비례(88.1%비91.7%)、백세포계수[(4.0±2.9)×109/L비(7.2±2.3)×109/L]、혈소판계수[(101±35)×109/L비(141±39 )×109/L ]명현증다,경도출혈비례(40.5%비19.0%) 현저감소( P<0.05혹 P<0.01);경6개월수방,여새록필정조비교,록필격뢰조심혈관사건(60.7%비27.4%)、불량반응발생솔(14.3%비10.8%) 균명현강저( P균<0.05)。결론:록필격뢰용우비S T 단태고심기경사환자급진관맥개입치료료효만의,안전성고,치득추엄。
Objective:To explore the application value of clopidogrel in patients with non ST segment elevation myo‐cardial infarction (NSTEMI) during emergency percutaneous coronary intervention (PCI) .Methods :A total of 168 NSTEMI patients treated in our hospital from Jan 2012 to Feb 2013 were randomly divided into clopidogrel group (n=84) and ticlopidine group (n=84) ,both groups received PCI .Therapeutic effect were observed and compared be‐tween two groups .Results:Compared with ticlopidine group , there were significant rise in percentage of TIMI blood flow grade 3 (88.1% vs .91.7% ) ,white blood cell counting [ (4.0 ± 2.9) 109/L vs .(7.2 ± 2.3) 109/L] and platelet counting [ (101 ± 35) 109/L vs .(141 ± 39) 109/L] ,and significant reduction in percentage of mild bleeding (40.5% vs .19.0% ) in clopidogrel group after operation 28d , P< 0.05 or < 0.01 ;compared with ticlopidine group , there were significant reductions in incidence rates of cardiovascular events (60.7% vs . 27.4% ) and adverse reactions (14.3% vs .10.8% ) in clopidogrel group after six‐month follow‐up ( P<0.05 both) .Conclusion:Clopi‐dogrel possesses satisfying therapeutic effect and high safety in patients with non ST segment elevation myocardial in ‐ farction during emergency percutaneous coronary intervention ,which is worth extension .